Opendata, web and dolomites

3DLT SIGNED

3D Living Tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DLT project word cloud

Explore the words cloud of the 3DLT project. It provides you a very rough idea of what is the project "3DLT" about.

yearn    rate    uncomplete    cutting    revenue    respect    edge    strictly    deeply    immuneonco    entire    remaining    ink    1st    asap    opportunity    preclinical    wounds    medicine    business    alive    pharmacological    tissues    performed    building    living    efficient    regenerative    structure    immunotherapies    cell    feasibility    market    clinical    resolution    2019    compartmentalization    3d    oncological    connecting    data    equal    expenditures    forecast    ones    company    reduce    printed    corresponding    2bln    markets    once    expenditure    96    acquire    proprietary    ip    share    cancer    requests    develops    companies    human    industrial    cosmetic    lymph    undertaking    mln    framework    3dln    prometheus    40mln    ematik    unreliable    bioprinting    commercial    fails    trials    safety    customers    composition    vitro    asymp    price    time    node    printing    pharma    connect    animal       jan    spends    strategy    drug    satisfy    care    predictive    estimating    commercialization    5bln    molecules    cells    excluding    times    tests    economic    contrary    drugs   

Project "3DLT" data sheet

The following table provides information about the project.

Coordinator
PROMETHEUS S.R.L. 

Organization address
address: VIA TRENTO 30
city: PARMA
postcode: 43122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.prometheus3d.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROMETHEUS S.R.L. IT (PARMA) coordinator 50˙000.00

Map

 Project objective

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

SMARTSLT (2019)

Smart speech and language tools for children's development.

Read More